What is Polycystic Ovarian Syndrome Treatment Market?
According to Centres for Disease Control and Prevention, United States, the polycystic ovarian syndrome is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The polycystic ovarian syndrome is a hormonal disorder that affects a woman’s hormone levels common among women of reproductive age. This syndrome can get during their childbearing years, which may affect their ability to have a child. The symptoms involve irregular periods, excess androgen or polycystic ovaries. Many women have polycystic ovarian syndrome but in one study found that 70 percent of women with PCOS hadn’t been diagnosed.
The market study is being classified and major geographies with country level break-up.
Pfizer Inc. (United States), Sanofi SA (France), Abbott Laboratories (United States), Bristol Myers Squibb (United States), Addex Therapeutics Ltd. (Switzerland), Crinetics Pharmaceuticals (United States), EffRx Pharmaceuticals SA (Switzerland), Neurocrine Biosciences (United States), Ferring BV (Switzerland), Johnson and Johnson (United States), Merck KGaA (Germany), Mylan N.V (United States), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Limited (Israel), Bayer AG (Germany) and AstraZeneca PLC (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are BIOCAD (Russia), Shire PLC (United States), Takeda Pharmaceutical Company Limited (Japan) and AbbVie Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Polycystic Ovarian Syndrome Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Polycystic Ovarian Syndrome Treatment market by Type, Application and Region.
On the basis of geography, the market of Polycystic Ovarian Syndrome Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Geographical Prevalence of Polycystic Ovarian Syndrome among Women
- Development of New Diagnostic Centres and Hospitals in Developing Countries
- Increase in Healthcare Expenditure
- Growing Focus on Preventive Healthcare
- Less Awareness about Polycystic Ovarian Syndrome among Women
- Development of Healthcare Infrastructure in Emerging Economies
- Growing Number of Regulatory Approvals
- Technological Advancements in the field of Medical Science
- Stringent Government Rules and Regulations
In January 2020, Evotec SE and Bayer AG have announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).
Key Target AudiencePolycystic Ovarian Syndrome Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase